Navigation Links
Anti-growth factor drugs raise hope and concern for treatment of children's eye diseases
Date:8/3/2009

Philadelphia, PA, 3 August 2009 A new class of antibody drugs may provide a powerful new tool for the treatment of eye diseases in children, but specialists need to be alert for the possibility of serious side effects, according to an editorial in the August Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus), published by Elsevier.

Dr. Robert L. Avery of Santa Barbara, Calif., discusses issues related to the use of antibodies against vascular endothelial growth factor (VEGF) in pediatric ophthalmology. The two anti-VEGF antibodies available so farbevacizumab and ranibizumabhave been rapidly adopted for the treatment of age-related macular degeneration (AMD), the leading cause of vision loss in older adults. The antibodies work by blocking the development of new blood vessels (angiogenesis).

Anti-VEGF antibodies were originally approved for use in cancer treatment, and there have been some safety concerns, including a possible increase in stroke risk. However, at the much smaller doses used in eye diseases, the two antibodies appear to be safe. However, in discussing the growing use of anti-VEGF antibodies in children, Dr. Avery sounds a cautious note. One study, also published in the August Journal of AAPOS, found that bevacizumab treatment in one eye of a child with eye disease also improved the condition in the other eye. This, along with other limited reports, suggests that the antibodies might leave the eye and enter the bloodstream, where they could potentially lead to side effects and complications.

Side effects are a special concern in children, who might be at higher risk because of their smaller size. Used in premature infants with an eye disease called retinopathy of prematurity, anti-VEGF antibodies could have the potential for harm to still developing organs.

These issues are particularly difficult because the anti-VEGF antibodies are not approved for use in chi
'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Study, meta-analysis examine factors associated with death from heatstroke
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
5. PA Health Department Survey Shows Impact of Income, Gender, Other Factors on Health and Access to Health Care
6. Researchers genetically engineer micro-organisms into tiny factories
7. Study Downgrades Gene as Heart Risk Factor
8. Severe heart defect likely caused by genetic factors
9. A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma
10. Aggressively Treating Cardiac Risk Factors May Reverse Ischemia
11. New peptide communication factor enabling bacteria to talk to each other discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 Senior Planning Services, providing ... a nonprofit organization providing the adult demographic education ... help seniors navigate the rough seas of applying for ... seniors on the topic of Medicaid eligibility and proper ... process of applying for this coverage. , Senior ...
(Date:11/26/2014)... November 26, 2014 ISI Telemanagement ... solutions, has been award the 2014 Lync ... This award comes as a great honor to ... the Lync ecosystem. Specifically, ISI offers an integrated ... of Lync communication, including voice, video, Lync IM, ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Call 866-997-4948 ... requirements or email the details on sales(at)researchmoz(dot)us , ... and drug discovery market 2014" with deep study of ... the result of high blood sugar. The global glucose ... linked to the growing number of diabetics in the ...
(Date:11/26/2014)... November 26, 2014 Bunion Bootie, the ... prices in an early celebration of the early holiday ... being offered at the promotional price of $29.95 each ... in addition to any automatic discounts applied when buying ... Bootie website for complete details. It’s simple: purchasing ...
(Date:11/26/2014)... Louisiana (PRWEB) November 26, 2014 ... pain relief and specialists in minimally invasive spine ... Samer Shamieh into the rapidly growing provider network ... The addition coincides with the network’s continuing ... medical treatment for Louisiana residents who are suffering ...
Breaking Medicine News(10 mins):Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2
... NORTH HOLLYWOOD, Calif., June 17 IPC The,Hospitalist Company, ... group practice, today announced that it continues to experience,favorable ... net,revenues to be in the range of $57 million ... range of $4.2 million to $4.6 million. Absent the,impact ...
... CEO Scott Kornhauser,announced the appointment of Bryan Hebert ... Hebert was a former consulting partner with,over 18 ... in the healthcare,industry., Mr. Hebert,s responsibilities will ... market share for Healthation. Prior to,joining Healthation, Mr. ...
... Men whose tumors recur after prostate cancer surgery are ... term if they undergo radiotherapy within two years of ... whose new tumors were growing fastest, according to results ... Hopkins Medical Institutions researchers reported June 18 in the ...
... in DNA, study finds, , , TUESDAY, June 17 (HealthDay ... when it comes to cancer risk, according to a ... research suggests that stringent dietary changes, getting more exercise ... hundreds of genes. Some of the changes positively ...
... HILL, N.C., June 17 Across industry sectors,sales ... common operational, strategic and time management practices,according to ... LLC., The study shows the client still ... spend 21 percent of their time,building solutions for ...
... the death rate and might need to be used ... News) -- Countering common medical theory, a new study ... many men whose prostate cancer recurs aggressively after surgery. ... that recurs after surgery seem to benefit from salvage ...
Cached Medicine News:Health News:IPC The Hospitalist Company, Inc. Provides Second Quarter 2008 Outlook 2Health News:IPC The Hospitalist Company, Inc. Provides Second Quarter 2008 Outlook 3Health News:IPC The Hospitalist Company, Inc. Provides Second Quarter 2008 Outlook 4Health News:Radiation therapy prolongs life in men with recurrent prostate cancer 2Health News:Lifestyle Changes Affect Cancer Genes 2Health News:Lifestyle Changes Affect Cancer Genes 3Health News:High-Performing Sales Forces Share Key Practices to Achieve Optimal Performance 2Health News:Radiation May Help When Prostate Cancer Returns 2Health News:Radiation May Help When Prostate Cancer Returns 3
(Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
(Date:11/26/2014)... 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, ... Dr. Helen Torley , President and Chief Executive ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:11/24/2014)... Juno Therapeutics today announced that the ... company,s JCAR015 chimeric antigen receptor product candidate.  The ... refractory B-cell acute lymphoblastic leukemia and was filed ... Center, where Phase 1 clinical trials are currently ... important news for patients who may benefit from ...
Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
For the quantitative determination of alanine aminotransferase in serum used in routine examination and monitoring of therapy and relapses....
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
Medicine Products: